TezEX
Research type
Research Study
Full title
The inflammatory profile of exacerbations in patients with severe asthma receiving tezepelumab: a retrospective and prospective observational study.
IRAS ID
343080
Contact name
David Jackson
Contact email
Sponsor organisation
Guy's and St. Thomas NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 28 days
Research summary
Asthma is a common condition, affecting over 5 million people in the UK. Severe asthma is defined as patients with asthma who require treatment with high dose inhaled steroids plus further medication to help control asthma symptoms. However, some individuals with asthma continue to have ongoing symptoms and asthma attacks, despite the medication they have been prescribed by their healthcare professional. We all know over the years; that long term steroids exposure can cause several side effects, affecting multiple parts of the body, like bones, skin, gut, obesity etc.
Over the last few years there has been a lot of research on targeted therapy in asthma and they are now the preferred treatment over oral corticosteroids, because of minimal side effects. For patients with severe asthma who have frequent exacerbations, NICE (The National Institute for Health and Clinical Excellence) has approved the use of medications called biologics, such as tezepelumab (Tezspire) (https://www.nice.org.uk/guidance/ta880/chapter/3-Committee-discussion).The main aim for the study is to investigate why some people with severe asthma continue to have asthma attacks (exacerbations) despite being on treatment with tezepelumab.
REC name
Wales REC 5
REC reference
24/WA/0346
Date of REC Opinion
20 Nov 2024
REC opinion
Favourable Opinion